dexrazoxane
Sign in to saveAlso known as DRX187, ADR-529, ICRF-187, (+)-1,2-bis(3,5-dioxo-1-piperazinyl)propane, (+)-(S)-4,4′-propylenedi-2,6-piperazinedione, dextrorazoxane
Dexrazoxane hydrochloride, sold under the brand name Zinecard among others, is a cardioprotective agent. It was discovered in 1972. The IV administration of dexrazoxane is in acidic condition with HCl adjusting the pH.
Research
810 papers- Dexrazoxane.2006
- Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.The Cochrane database of systematic reviews · 2022
- Dexrazoxane.2026
- Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
- Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines.Cureus · 2023
via PubMed
Wikidata facts
- Mass
- 268.117155
Show 6 more facts
- chemical formula
- C₁₁H₁₆N₄O₄
- canonical SMILES
- CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
- isomeric SMILES
- C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
- World Health Organisation international non-proprietary name
- dexrazoxane
- defined daily dose
- 1.5
- Commons category
- Dexrazoxane
via Wikidata · CC0
~3 min read
Article
3 sectionsContents
- Medical uses
- Mechanism
- References
Dexrazoxane hydrochloride, sold under the brand name Zinecard among others, is a cardioprotective agent. It was discovered in 1972. The IV administration of dexrazoxane is in acidic condition with HCl adjusting the pH.
==Medical uses== Dexrazoxane has been used to protect the heart against the cardiotoxic side effects of chemotherapeutic drugs such as anthracyclines, such as daunorubicin or doxorubicin or other chemotherapeutic agents. However, in July 2011 the European Medicines Agency (EMA) released a statement restricting use only in adult patients with cancer who have received > 300 mg/m2 doxorubicin or > 540 mg/m2 epirubicin and general approval for use for cardioprotection. That showed a possibly higher rate of secondary malignancies and acute myelogenous leukemia in pediatric patients treated for different cancers with both dexrazoxane and other chemotherapeutic agents that are associated with secondary malignancies. On 19 July 2017, based on evaluation of the currently available data the European Commission issued an EU-wide legally binding decision to implement the recommendations of the Committee for Medicinal Products for Human Use (CHMP) on dexrazoxane and lifted its 2011-contraindication for primary prevention of anthracycline-induced cardiotoxicity with dexrazoxane in children and adolescents where high doses (≥ 300 mg/m3) of anthracyclines are anticipated.